Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Vicadrostat (BI 690517) Alone and With Empagliflozin in CKD
NCT05182840Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 29
01
Overview
A Phase 2 trial of vicadrostat in chronic kidney disease (CKD), sponsored by Boehringer Ingelheim. Started Jan 2022; status: completed.
02
Drugs
vicadrostat
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05182840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05182840.